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Abstract
Purpose. This paper reports the procedures and the clinical results of a series of surgical treatments for skeletal metastases
from soft tissue sarcomas.
Subjects and methods. Surgical treatment of metastatic bony lesions from soft tissue sarcomas has been carried out over
a 20 year period (1975± 1996). Thirty-two patients developed skeletal metastases from soft tissue sarcomas, and 20 of these
cases received surgical treatment. The 23 metastatic bony lesions in these 20 patients were treated using the following
surgical approaches: wide resection with prosthetic replacement in ® ve lesions, wide or marginal resection without
reconstruction in four lesions, intramedullarly nailing with curettage and methylmethacrylate cementation in four lesions,
marginal resection of vertebral body with replacement by a ceramic prosthesis in three lesions, laminectomy in three
lesions, intramedullarly nailing in two lesions, and curettage in two lesions.
Results. Relief of pain was achieved in 17 of the 20 patients. The ambulatory status of the patients with metastasis in the
lower extremity or periacetabular region was signi® cantly improved in nine of 10 cases. Seventeen patients died of disease,
with a mean survival period of 17.9 months after surgery for metastasis.
Discussion. Although surgical treatment for skeletal metastases from soft tissue sarcomas cannot save the life of the
patient, it can be of value in improving their well-being and overall quality of life. In these cases, surgical intervention may
be more frequently indicated than in tumors with an osteoblastic or mixed pattern.
Introduction
Soft tissue sarcomas have a potential for distant
metastasis, and a signi® cant proportion of cases are
resistant to recent multimodal treatments involving
chemotherapy, radiotherapy and wide local resec-
tion.
1,2 Lung metastasis appears to be most common
in patients with distant tumor recurrence, is life
threatening, and from recent reports describing in-
creased survival, may be best countered through
aggressive metastasectomy.
3,4
In contrast, skeletal metastasis occurs with a
much lower incidence when compared with the
lung,
5,6 but may cause some orthopedic problems.
Metastatic lesions from soft tissue sarcomas are
characterized by osteolytic destruction with a per-
meative or moth-eaten pattern.
7 They increase the
risk of pathological or impending fracture and insta-
bility of the spine which may in turn lead to intrac-
table pain and disfunction.
7,8 Almost half of the
metastatic bony lesions sustained pathological frac-
ture in the previous study.
7 Therefore, appropriate
surgical treatments for metastatic bony lesions must
be considered for improving the patient’s quality of
life, and possibly prolonging their survival.
Apart from a couple of sporadic cases,
8± 10 there
have been few studies undertaken to analyse the
outcome of surgical treatment for skeletal metastasis
from soft tissue sarcomas. In the present report, the
authors describe the results of aggressive surgeries,
including wide local resection with prosthetic re-
placement, to deal with these cases.
Subjects and methods
Thirty-two patients with skeletal metastasis were
identi® ed from 302 cases of soft-tissue sarcomas at
the authors’ institutions over a 20-year period
(1975± 1996). The patients’ primary lesions were
removed with no evidence of recurrence. Skeletal
metastasis was diagnosed by radiological ® ndings,
including a bone scan. Direct invasion to local
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bones from the primary soft tissue sarcomas was
excluded from skeletal metastasis. Twenty of the 32
patients with bone metastasis received surgical treat-
ments for the metastatic lesion, and three of the 20
patients sustained an additional surgery for another
metastatic lesion on the same day or at a later time
point. All lesions were con® rmed histologically as
metastasis from the original sarcoma after surgery.
Surgery was not indicated for the remaining 12
patients because their general condition was too
poor due to metastases to other important organs,
or because the skeletal metastases were too dissemi-
nated to be addressed by surgical intervention. The
clinical characteristics of the patients who under-
went surgical treatment for skeletal metastases are
summarized in Table 1. The fracture status of the
metastatic lesions is also included: impending frac-
ture in seven lesions, pathological fracture in 13
lesions, and no fracture in three lesions. Surgery was
indicated based on the following parameters: life
expectancy subjectively estimated to be more than 1
month, and evidence of: (1) solitary bone metastasis
without any other metastasis, or with minimal
metastases in other organs; (2) bone metastases,
solitary or multiple, with pathological fracture or
impending fracture; or (3) bone metastases, solitary
or multiple, causing neurological symptoms such as
paresis and intractable pain.
Twenty lesions from 19 patients presented with
pain due to the metastatic lesion, but three lesions
(the sacrum in case 19, the rib in case 11 and the
humerus in case 20) were pain free and detected
radiologically. The surgical procedures for 23
metastatic bony lesions were as follows: wide resec-
tion with prosthetic replacement in ® ve lesions; wide
or marginal resection without reconstruction in four
lesions; intramedullarly nailing with curettage and
methylmethacrylate cementation in four lesions;
marginal resection of vertebral body with replace-
ment by a ceramic prosthesis
11 in three lesions;
laminectomy in three lesions; intramedullarly nail-
ing in two lesions; and curettage in two lesions. A
periacetabular lesion was reconstructed by a newly
designed prosthesis with a constrained joint mech-
anism.
12
In 13 patients (cases 1± 4, 6, 9± 12, 14, 18, 19 and
20) surgery was undertaken to remove the
metastatic tumor with the expectation of prolonging
the patient’s survival. Laminectomy was performed
as an emergency surgery in three patients (cases 15,
16 and 17) to prevent paralysis, and followed by
postoperative radiotherapy (40± 50 Gy). Palliative
curettage was performed for the huge iliac mass
(case 13) which caused intractable pain due to
severe compression of the femoral nerve. In the
remaining three cases (cases 5, 7 and 8), the opera-
tions were performed palliatively to relieve pain and
ease nursing care.
Pain relief for 17 patients with pain prior to
surgery, and walking ability in 10 patients with
surgery of the lower extremity and the periacetabu-
lar region, were evaluated according to the criteria
of Enneking et al.
13 The follow-up period ranged
from 5 to 85 months (mean, 36.3 months) after the
date of the ® rst admission. Survival was calculated
according to the methods of Kaplan and Meier.
14
Survival points were based on survival after the ® rst
surgery for a metastatic bony lesion.
Results
Local control
Local recurrence after tumor resection at the wide
or marginal margin was not detected clinically dur-
ing follow-up period. Mild wound infections devel-
oped in two patients, both of which resolved with
antibiotic therapy. No major complications, such as
deep infection, were observed. There were no in-
stances of prosthetic dislocation, loosening, or fail-
ure. Fig. 1 and Fig. 2 show the representative cases
that received wide local resection and prosthetic
replacement for the solitary metastatic lesion.
Pain relief and function
Fifteen out of 19 patients with pain prior to surgery
achieved relief of pain, restored mobility and the use
of affected limbs within 1 week after surgery: no
medication was used for 10 patients; non-narcotic
medication was used only occasionally for ® ve pa-
tients. They demonstrated improvement compared
with their preoperative pain status, and increased
independence during activity. Ease of care was en-
hanced and pain relief was achieved, even in non-
ambulatory patients, in spite of the extent of the
disease. The remaining four patients needed inter-
mittent or continuous narcotics after surgery; one
patient (case 5) failed to be stabilized with internal
® xation due to rapid destruction of the lesion, and
three patients achieved little pain relief after
laminectomy. Relief from pain was achieved in all
the patients whose treatment involved tumor resec-
tion and prosthetic replacement for their spinal
metastases (Fig. 3).
In terms of ambulatory status, two were able to
walk without any supports after surgery, and four
could walk with a cane, two could walk with
crutches, and two required a wheelchair. Because of
the palliative mass reduction of the huge iliac met-
astasis (case 13), intractable pain due to com-
pression of the femoral nerve disappeared
immediately after surgery, and the patients were
able to walk for 6 months until their condition
deteriorated (Fig. 4). In three cases, laminectomy
reduced and temporarily prevented paralysis, but
resulted in a complete paraplegia after 2± 4 weeks
due to tumor progression. Tumor resection and
prosthetic replacement for spinal metastasis pre-Surgical treatment for skeletal metastases from soft tissue 109
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Fig. 1. (Left) A 26-year-old male with metastasis of malignant schwannoma to the femur. An osteolytic lesion with a pathological
fracture is discernible. (Right) The patient was ambulatory after wide resection and prosthetic replacement (Kotz system) for 4 months
until his illness reached a terminal condition.
vented neurological dysfunction during the follow-
up periods in these patients.
Survival
The overall mean survival period for the 20 patients
who received surgical treatment, calculated from
surgery for bone metastasis, was 13.4 months
(range, 4± 57 months). Of these 20 patients, 17 died
of diseases with a mean survival period of 17.9
months (range, 5± 57 months) from the time of
surgery, 14 died of pulmonary metastases, and three
(cases 15, 17 and 19) died of disseminated bone
metastases. Two patients (cases 1 and 2) died of
other causes, with survivals of 12 and 4 months
from surgery for bone metastases, and only one
patient is now alive without any metastasis 7 months
after surgery. The overall estimated survival for pa-
tients with surgical treatment for bone metastasis
from sarcomas of soft tissue are shown in Fig. 5.
One and 2-year survivals from surgery for bone
metastasis were 62.4% and 24.9%, respectively. No
5-year survivors were recorded. On the other hand,
the remaining 12 patients, for whom surgery was
not indicated, died with a mean survival period of
3.5 months (range, 1± 5 months).
Discussion
Skeletal metastasis has been considered as a he-
matogenous dissemination and a terminal stage in
the lives of sarcoma patients.
2,5,6,15 Because of this
poor prognosis, metastatic bony lesions are not al-
ways managed aggressively. However, advances in
the oncological management of patients with dis-
seminated cancer have led to increased survival and
quality of life.
16 Moreover, much experience has
been gathered from the ® eld of limb-saving proce-
dures in primary tumors of the musculoskeletal sys-
tem, and radical local excision and endoprosthetic
replacement have been used commonly for the man-
agement of isolated skeletal metastases from can-
cers.
8,9,12,17 Therefore, orthopedic management for
patients with skeletal metastasis from sarcomas must
be also encouraged, even if their survival periods are
limited. Despite the palliative nature of the treat-
ment, an aggressive program of fracture manage-
ment for long bones utilizing current techniquesSurgical treatment for skeletal metastases from soft tissue 111
Fig. 2. (Left) A 67-year-old male with metastasis of malignant ® brous histiocytoma of the knee to the acetabulum. An osteolytic lesion
with a pathological fracture is discernible. (Right) The patient was ambulatory after wide resection and prosthetic replacement for 12
months until his illness reached a terminal condition.
with internal ® xation to provide secure stabilization,
or prosthetic replacement to restore joint function,
provides considerable bene® ts. From this perspec-
tive, a diffuse involvement of skeleton by soft tissue
sarcomas may not be a contraindication to surgical
treatment.
In the present study, methylmethacrylate was
used in ® ve cases for the internal ® xation of patho-
logical fractures, a procedure that has been used
widely in dealing with metastasis from carci-
noma.
18,19 This procedure afforded immediate sta-
bility and enabled the patients to resume walking
with good relief of pain in all cases. Since metastasis
from soft tissue sarcomas leads almost exclusively to
osteolytic lesions,
7 stabilization with methyl-
methacrylate appears to be a successful strategy for
countering this possibility. Recent advances in pros-
theses have led to endoprosthetic replacement as an
option for the treatment of metastatic bony lesions
in addition to primary bone tumors.
17,20 The use of
an endoprosthesis permits tumor resection and
rapid stabilization in a single surgical event. In all of
the ® ve cases involving the lower extremity of a limb
where this procedure was employed, pain relief was
achieved and the ambulatory status was enhanced
immediately following surgery. Since a local recur-
rence has not been detectable during the follow-up
period, stabilization via endoprosthetic replacement
appears to work well for the treatment of lesions
metastasizing to the proximal femur and humerus
from soft tissue sarcomas. By using internal ® xation
with methylmethacrylate or endoprosthetic replace-
ment, pain relief was achieved satisfactorily in most
cases, and considerable function was gained in the
cases involving a lower limb extremity. Therefore,
the surgical procedures employed for dealing with
metastases from carcinomas are also applicable for
skeletal metastasis from soft tissue sarcomas.
The spine is the most common site of skeletal
metastasis in soft-tissue sarcomas,
7 as well as in
most carcinomas, most likely via Batson’s vertebral
vein system,
21 raising the possibility of surgical man-
agement as a treatment option. Laminectomy and
postoperative radiotherapy were performed on an
emergency basis in only three patients. This pallia-
tive treatment prevented paralysis temporally but
could not relieve pain due to spinal instability. How-
ever, in three cases who received tumor resection
and prosthetic replacement for their spinal lesion,
pain relief was achieved because of spinal cord112 H. Yoshikawa et al.
Fig. 3. (Left) A 34-year-old man had severe neck pain, resisting any analgesics because of C5 metastasis from synovial sarcoma of
the popliteal region. A destructive metastasis with compression fracture of the C5 body is discernible. (Right) The affected vertebra was
resected and replaced with a ceramic prosthesis. The severe neck pain was relieved after surgery.
decompression and restoration of spinal stability,
and survival after surgery extended beyond 1 year
(mean, 17 months). Although radical resection of
the lesions in the spine is impossible, mass reduction
of the tumor may ensure prevention of local recur-
rence for a long period, and increase the ef® cacy of
radiation in eradicating microscopic foci of the tu-
mor around the spinal cord.
11 Therefore, if surgical
treatment is indicated, both decompression of the
neural tissues by tumor resection and restoration of
spinal stability, in spite of their aggressiveness, seem
to be essential to restore neurological function, con-
trol pain, and provide patients with improved mo-
bility and quality of life. Prosthetic replacement
surgery, with which decompression and stabilization
can be achieved simultaneously, is an excellent
choice for vertebral body metastasis.
In terms of prognosis, mean survival from surgery
for bone metastasis is 13.4 months for 20 patients,
which is similar to the ® ndings of previous reports
describing the clinical outcomes in cases of skeletal
metastases from carcinomas; for example, 5.6
months in patients who received endoprosthetic re-
placement for proximal femur,
20 and 10 months in
patients who received intramedullarly nailing and
cementation of the humerus,
19 and 15.4 months in
patients with internal ® xation of a pathological frac-
ture.
18 Of particular note in our study is that in three
of the four alveolar soft tissue sarcomas, the mean
survival period following surgery was more than 3
years, indicating that surgical intervention seems
well indicated for this particular tumor, and longer
survival might be expected in other cases, for exam-
ple, skeletal metastases from thyroid cancer.
16 Un-
fortunately, in spite of aggressive surgical treatment,
it is disappointing that no 5-year survivor after
surgery was recorded, although cases of a greater
than 5-year survival period after metastasectomy for
lung or lymphnode metastases have been re-
ported.
4,22 While somewhat speculative, it is reason-
able to conclude that metastases to the skeleton may
be considered to be a more signi® cant indicator of a
poor outcome when contrasted with lung or
lymphnode for patients with soft tissue sarcomas.
In summary, surgical treatment for skeletal metas-
tases from soft-tissue sarcomas cannot save the lifeSurgical treatment for skeletal metastases from soft tissue 113
Fig. 4. (Top) A 65-year-old man had severe radiated pain of the right lower extremity and severe restriction of extension of the right
hip, because of a huge metastatic lesion (arrows) of the ilium from leiomyosarcoma of the stomach. (Bottom) The radiated pain was
relieved immediately after a palliative curettage, and the patient could walk for 6 months until his illness reached a terminal condition.
A CT scan 1 month after surgery shows only a residual cystic lesion (arrows).
Fig. 5. Overall estimated survival for patients with surgical
treatment for skeletal metastasis from soft tissue sarcomas.
Survival calculated from time of surgery for metastatic bony
lesion.
of the patient, but may be of value in improving
their well-being and overall quality of life. We be-
lieve that, in these cases, surgical intervention may
be more frequently required than for metastatic
tumors with an osteoblastic or mixed pattern, such
as prostatic or breast carcinomas. Further studies
will be required to con® rm that surgical intervention
in cases of skeletal metastasis from soft tissue sarco-
mas leads to improvements in patient survival.
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